Activist DOMA Perpetual Launches Proxy Battle, Nominates Three Directors, Opposes Share Plans and Executive Pay

summarizeSummary

Activist investor DOMA Perpetual has filed its preliminary proxy statement, formally launching a proxy contest to elect three independent directors to Pacira BioSciences' board and opposing management's executive compensation and proposed stock incentive plans.

check_boxKey Events

• Activist Launches Proxy Contest

  DOMA Perpetual, holding approximately 7.5% of outstanding shares, has filed its preliminary proxy statement to solicit votes for three independent director nominees at the 2026 Annual Meeting.

• Opposes Executive Compensation

  The activist recommends voting AGAINST the company's advisory proposal to approve executive compensation, citing a misalignment with shareholder returns and excessive insider enrichment.

• Challenges Stock Incentive Plans

  DOMA Perpetual urges shareholders to vote AGAINST amendments to the 2011 Stock Incentive Plan and 2014 Employee Stock Purchase Plan, which would authorize an additional 3,000,000 shares, representing a potential dilution of over 7.6%.

• Advocates for Strategic Review and Potential Sale

  The activist argues that the current board's strategy is flawed and that new directors are needed to initiate a comprehensive review of strategic alternatives, including a potential sale of the company, to mitigate significant risks related to EXPAREL patent litigation and lack of diversification.

auto_awesomeAnalysis

Activist investor DOMA Perpetual has formally launched its proxy contest, filing a preliminary proxy statement to solicit shareholder votes for three independent director nominees. This filing directly challenges Pacira BioSciences' current board and management, citing sustained economic underperformance, excessive executive compensation, and a flawed capital allocation strategy. DOMA Perpetual, holding a significant 7.5% stake, is also urging shareholders to vote against the company's proposed amendments to its 2011 Stock Incentive Plan and 2014 Employee Stock Purchase Plan, which would authorize an additional 3,000,000 shares, representing a potential dilution of over 7.6%. The activist argues that the company's reliance on EXPAREL, coupled with patent litigation risks and a lack of diversification, puts shareholder value at extreme risk, advocating for a strategic reset including a potential sale of the company. This intensifies the ongoing proxy battle, following the company's definitive proxy filing on April 28, 2026, and signals a critical juncture for Pacira's governance and strategic direction.